Calc Function

    • Calcs that help predict probability of a diseaseDiagnosis
    • Subcategory of 'Diagnosis' designed to be very sensitiveRule Out
    • Disease is diagnosed: prognosticate to guide treatmentPrognosis
    • Numerical inputs and outputsFormula
    • Med treatment and moreTreatment
    • Suggested protocolsAlgorithm

    Disease

    Select...

    Specialty

    Select...

    Chief Complaint

    Select...

    Organ System

    Select...

    Patent Pending

    REACH-B Score for Hepatocellular Carcinoma (HCC)

    Estimates risk of hepatocellular carcinoma (HCC) in patients with chronic hepatitis B.
    Favorite
    Pearls/Pitfalls

    • Derived and validated primarily in East Asian cohorts; may have limited applicability to other populations.

    • Excludes factors such as alpha fetoprotein and alcohol use, which are also known to be associated with progression to cirrhosis and HCC.

    Female
    0
    Male
    +2
    30–34
    0
    35–39
    +1
    40–44
    +2
    45–49
    +3
    50–54
    +4
    55–59
    +5
    60–65
    +6
    <15
    0
    15–44
    +1
    ≥45
    +2
    Negative
    0
    Positive
    +2
    <300 (undetectable)
    0
    300–9,999
    0
    10,000–99,999
    +3
    100,000–999,999
    +5
    ≥10⁶
    +4

    Result:

    Please fill out required fields.

    Next Steps
    Evidence
    Creator Insights

    Advice

    May help guide decision to initiate treatment in patients with chronic hepatitis B and thus help prevent progression to HCC.

    Formula

    Addition of the selected points:

    Variable

    Points

    Sex

    Female

    0

    Male

    2

    Age, years

    30–34

    0

    35–39

    1

    40–44

    2

    45–49

    3

    50–54

    4

    55–59

    5

    60–65

    6

    ALT, U/L

    <15

    0

    15–44

    1

    ≥45

    2

    HBeAg

    Negative

    0

    Positive

    2

    Hepatitis B virus DNA level, copies/mL

    <300 (undetectable)

    0

    300–9,999

    0

    10,000–99,999

    3

    100,000–999,999

    5

    ≥106

    4*

    *The risk score attributed to HBV DNA ≥106 copies/mL was less than that for HBV DNA of 100,000–999,999 copies/mL because most patients with HBV DNA ≥106 copies/mL were also HBeAg positive, thus sharing the associated higher score for this category.

    Facts & Figures

    Interpretation:

    REACH-B Score

    HCC risk

    3-year

    5-year

    10-year

    0

    0.0%

    0.0%

    0.0%

    1

    0.0%

    0.0%

    0.1%

    2

    0.0%

    0.0%

    0.1%

    3

    0.0%

    0.1%

    0.2%

    4

    0.0%

    0.1%

    0.3%

    5

    0.1%

    0.2%

    0.5%

    6

    0.1%

    0.3%

    0.7%

    7

    0.2%

    0.5%

    1.2%

    8

    0.3%

    0.8%

    2.0%

    9

    0.5%

    1.2%

    3.2%

    10

    0.9%

    2.0%

    5.2%

    11

    1.4%

    3.3%

    8.4%

    12

    2.3%

    5.3%

    13.4%

    13

    3.7%

    8.5%

    21.0%

    14

    6.0%

    13.6%

    32.0%

    15

    9.6%

    21.3%

    46.8%

    16

    15.2%

    32.4%

    64.4%

    17

    23.6%

    47.4%

    81.6%

    Dr. Hwai-I Yang

    About the Creator

    Hwai-I Yang, PhD, is an associate research fellow at the Genomics Research Center in Taipei, Taiwan. He is also an adjunct associate professor at the Graduate Institute of Clinical Medicine at National Yang-Ming University. Dr. Yang’s primary research is focused on hepatitis epidemiology, translational epidemiology, immunoepidemiology of viral hepatitis, and immunoprevention of major cancers.

    To view Dr. Hwai-I Yang's publications, visit PubMed